Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1388320/000121390020015104/ea123121-8k_actiniumpharma.htm
December 2023
March 2023
February 2023
December 2022
December 2022
October 2022
June 2022
April 2022
November 2021
September 2021
Please wait while we load the requested 8-K report or click the link below:
https://last10k.com/sec-filings/report/1388320/000121390020015104/ea123121-8k_actiniumpharma.htm
Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Actinium Pharmaceuticals, Inc..
Actinium Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:
Material Contracts, Statements, Certifications & more
Actinium Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits
Ticker: ATNMEvents:
CIK: 1388320
Form Type: 8-K Corporate News
Accession Number: 0001213900-20-015104
Submitted to the SEC: Tue Jun 16 2020 4:21:18 PM EST
Accepted by the SEC: Tue Jun 16 2020
Period: Tuesday, June 16, 2020
Industry: Pharmaceutical Preparations